JKN2502

Part I: Study Objectives Primary Objective: To evaluate the safety and tolerability of JKN2502 administered intravenously in healthy participants in the Chinese trial. Secondary Objectives: 1) To evaluate the pharmacokinetic characteristics of JKN2502 administered intravenously in healthy participants in the Chinese trial; 2) To evaluate the effect of plasma drug concentration on the QT/QTc interval after intravenous administration of JKN2502 in healthy participants in the Chinese trial. Exploratory Objective: To preliminarily analyze the metabolites of JKN2502 in plasma, urine, and feces. Part II: Study Objectives Primary Objective: To evaluate the pharmacokinetic characteristics of a single intravenous infusion of JKN2502 in participants with normal renal function and varying degrees of renal impairment. Secondary Objective: To evaluate the safety and tolerability of intravenous infusion of JKN2502 in participants with normal renal function and mild, moderate, and severe renal impairment. Exploratory Objective: To explore the correlation between pharmacokinetic parameters of JKN2502 and renal function indicators (such as eGFR, serum creatinine, etc.).